

AKUH Inpatient. Percent Resistant Jan-Dec 2016														
Organism	n*	AMP	ATM	CEF	CXM	CRO	CAZ	TZP	IPM	AMK	GEN	CIP	SXT	MEM
<i>Acinetobacter group</i>	723	NT	44	NT	NT	NT	77	79	73	40	46	84	56	NT
<i>E.coli</i>	2063	91	61	79	79	79	NT	27	10	6	37	73	74	NT
<i>Enterobacter species</i>	179	100	42	48	48	48	NT	19	13	8	25	19	65	NT
<i>Klebsiella pneumoniae</i>	792	100	55	63	63	63	NT	24	19	16	32	33	58	NT
<i>Pseudomonas aeruginosa</i>	900	NT	27	NT	NT	NT	25	13	32	18	23	25	NT	NT
<i>Proteus mirabilis</i>	115	78	18	55	60	55	NT	6	NT	14	40	47	74	4
		CAZ	LEV	SXT	TET	MINO	MEM							
<i>Stenotrophomonas maltophilia</i>	146	25	2	7	25	NT	NT	NT	NT	NT	NT	NT	NT	NT
<i>Burkholderia cepacia</i>	111	9	16	13	NT	0	22	NT	NT	NT	NT	NT	NT	NT
		AMP	CLR	OX	FD	PEN	ERY	CLI	VAN	TET	GEN	LEVO/CIP	SXT	
<i>Enterococcus species</i>	1117	53	17	NT	NT	NT	NT	NT	27	43	29	76	NT	NT
<i>Staphylococcus aureus</i>	1030	NT	1	69	6	82	40	25	0	36	33	27	38	NT
<i>Coagulase negative Staph.</i>	1485	NT	5	76	38	70	69	42	0	31	35	26	53	NT
AKUH Outpatient. Percent Resistant JAN-Dec 2016														
Organism	n*	AMP	ATM	CEF	CXM	CRO	CAZ	TZP	IPM	AMK	GEN	CIP	SXT	MEM
<i>Acinetobacter group</i>	928	NT	44	NT	NT	NT	52	55	51	32	47	61	47	NT
<i>E.coli</i>	15286	89	52	70	71	66	NT	17	5	4	37	68	71	NT
<i>Enterobacter species</i>	854	100	43	47	79	47	NT	20	15	13	34	33	45	NT
<i>Klebsiella pneumoniae</i>	3174	100	47	53	53	53	NT	23	19	20	33	33	50	NT
<i>Pseudomonas aeruginosa</i>	3906	NT	22	NT	NT	NT	21	10	17	17	25	29	NT	NT
<i>Proteus mirabilis</i>	569	69	14	35	41	35	NT	1	NT	11	34	33	69	1
		CAZ	LEV	SXT	TET	MINO	MEM							
<i>Stenotrophomonas maltophilia</i>	103	43	6	3	36	NT	NT	NT	NT	NT	NT	NT	NT	NT
<i>Burkholderia cepacia</i>	792	4	15	14	NT	0	22	NT	NT	NT	NT	NT	NT	NT
		AMP	CLR	OX	FD	PEN	ERY	CLI	VAN	TET/DOXY	GEN	LEVO/CIP	SXT	
<i>Enterococcus species</i>	3489	20	18	NT	NT	NT	NT	NT	5	78	3	66	NT	NT
<i>Staphylococcus aureus</i>	4125	NT	0	60	7	95	44	19	0	33	33	12	50	NT
<i>Coagulase negative Staph.</i>	3137	NT	8	58	47	90	73	28	0	37	27	47	54	NT

*n = Total Isolates

ABBREVIATIONS

NT - Not Tested
 AMK - Amikacin
 AMP - Ampicillin
 ATM - Aztreonam
 CAZ - Ceftazidime
 CEF - Cefixime
 CLI - Clindamycin
 CIP - Ciprofloxacin
 OX - Oxacillin
 CLR - Chloramphenicol
 CRO - Ceftriaxone
 CXM - Cefuroxime
 DOXY-Doxy-cycline
 ERY - Erythromycin
 FD - Fusidic acid
 GEN - Gentamicin
 IPM - Imipenem
 LEVO-Levofloxacin
 MEM-Meropenem
 MINO-Minocycline
 OFX- Ofloxacin
 PEN - Penicillin
 RIF - Rifampicin
 STREP - Streptomycin
 SXT - Cotrimoxazole
 TE - Tetracycline
 VAN - Vancomycin

ABBREVIATIONS

NT - Not Tested
 AMK - Amikacin
 AMP - Ampicillin
 ATM – Aztreonam
 AMT- Amphotericin B
 CIP - Ciprofloxacin
 CAP - Capreomycin
 CAZ - Ceftazidime
 CEF - Cefixime
 CLI - Clindamycin
 CLR -Chloramphenicol
 CRO - Ceftriaxone
 CXM – Cefuroxime
 ERY - Erythromycin
 ETHAM - Ethambutol
 ETHION - Ethionamide
 FD - Fusidic acid
 FLUC- Fluconazole
 GEN - Gentamicin
 IPM – Imipenem
 INH – Isoniazid
 LEVO-Levofloxacin
 OFX/ Ofloxacin
 K-Kanamycin
 PEN - Penicillin
 RIF - Rifampicin
 STREP - Streptomycin
 SXT - Cotrimoxazole
 TET - Tetracycline
 VAN – Vancomycin
 VORI- Voriconazole

AKUH /All patients. Percent Resistant. Jan-Dec 2016										
Organism	n *	AMP	CLR	CEF	CRO	ERY	CIP	SXT	TET	
<i>Aeromonas hydrophila</i>	140	100	NT	30	30	NT	11	32	NT	
<i>Campylobacter species</i>	414	100	NT	NT	NT	5	91	NT	29	
<i>Salmonella Typhi, Para A,B & C</i>	1534	39	38	0.1	0.1	NT	87**	39	NT	
<i>Salmonella spp.</i>	223	39	13	7	7	NT	16	40	NT	
<i>Shigella spp.</i>	146	57	24	18	18	NT	15	81	NT	
<i>Vibrio cholerae</i>	95	12	0	NT	NT	NT	0	57	41	
		AMP	CLR	PEN	CRO	ERY	CIP	SXT	TET	
<i>Haemophilus influenzae</i>	402	8	5	NT	0	NT	35	75	10	
<i>Moraxella catarrhalis</i>	113	100	9	NT	NT	26	33	44	17	
<i>Neisseria gonorrhoea</i>	103	NT	NT	66	0	NT	95	NT	77	
		CLI	PEN	CLR	ERY	VAN	LEVO/ OFX	SXT	TET	
<i>Beta haemolytic strep. A</i>	360	29	0	15	31	0	7	NT	NT	
<i>Streptococcus pneumoniae</i>	355	NT	16	5	40	0	19	81	55	
		INH	RIF	STREP	ETHAM	CAP	OFX	ETHION	AMK	K
<i>Mycobacterium tuberculosis</i>	1671	18	11	12	11	1	20	3	1	1
		AMK	AMC	DOX	IPM	CIP	SXT			
<i>Nocardia spp</i>	22	0	54	4	66	50	4			
		AMT	FLUC	VORI						
<i>Candida spp</i>	709	0	22	2						

*n = Total Isolates, ** Intermediate resistant *Salmonella Typhi* are included.

Note: Susceptibility profiles are derived from all specimen received by the Clinical Microbiology Laboratory. Antibiotic susceptibilities of bacteria recovered from specific wards or populations may differ.

Logo

Aga Khan University Hospital

Clinical Laboratory

Microbiology

ANTIBIOTIC SUSCEPTIBILITY REPORT

Jan-Dec 2016

Telephone: 34930051 ext. 1680,1682
 Between 9:00 -5:00 pm
 During weekdays (Mon-Fri)